About PeptiGrowth
PeptiGrowth Inc., a subsidiary of Mitsubishi Corporation, is supporting the growth of the regenerative medicine and cell therapy industry by offering a series of synthetic peptides that function as growth factors. Our peptides are chemically synthesized (scalable to kilograms), completely animal component-free, and can achieve highly consistent quality, excellent scalability, and reasonable cost. PeptiGrowth has launched 6 products – HGF, TGF-β1 inhibitor, BDNF, Noggin, and BMP 4 or 7 selective inhibitor peptides – and is launching more products – [PDGF-AA, VEGF, Wnt3a, TPO, and FGF2 peptides] toward the end of 2023- early 2024.